{"name":"Silverback Therapeutics","slug":"silverback-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":84278000,"revenueGrowth":-5.5,"grossMargin":0,"rdSpend":13181000,"netIncome":-171298000,"cash":41317000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"date":"2026-03-09","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxPeGo5THRpSFlBQWZTd0VZem81b2xOTFpBWkoxU0xHSlRJdm1zYU15NGhLWXRQSURnUGlQc3JKdllFOG1YTFlGVUFUbWV2NnVLY2VXbm5fYWxtVFdKOGZxXy1Db0RFOTZYUHNQSFQ3VTl1bU1WWHJCZ0NBTEg1STlZQmxIOE1sTG1BbndYTjduWFA0NUx3WnRqQkRyQTVxZXhPSlBONlNWSl8wT2J1WG8yNmhSeHlEeEItM1pQLXZ1YURMaHluN09UdGJLOGtXbGNqdkk0RGpTa2FpZXg1UG9LWnhFemR2d014dkw0bm5jWk5DZ2l6dm95UjIzaVhqR0NqcERSRXJlOGlyQ0gxYVVpX3ZsWmI?oc=5","date":"2026-02-23","type":"earnings","source":"Investing News Network","summary":"ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences - Investing News Network","headline":"ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results an","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE5vRTMwODRQa2k4cFZaOVFmNndFYnVtdF8zODQ5Mk1HeUdfdmZ6NU42a1hFX2xpLWc2QmlxOHl5ZWN2SHNuU25jemtRUFVFUFVFWXdTU3g4V3lCSC1EMlVsOXBn?oc=5","date":"2025-09-02","type":"pipeline","source":"Fierce Pharma","summary":"Laura Shawver - Fierce Pharma","headline":"Laura Shawver","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxOM21NWGJUU3VHRnF1NzFjNk1RelV4RGVxWXVYN19jNGhVNjZIekt5YktjYTRBejRQeGE2VWd6V0RESG92eldPZms4RDlFZ0kxWmdtb0Z2ODFtR1ZTQWJCM0Nha0p4YXhoazJrdV9rYzVUVDlxTnAyVXRMOTdkeTR1S3ZyMDJ3TW4xU3lQa0pNY1dzeGt1R0E4Xy14bFlISWJkck1WRUdDMTFzOW5YOWlHalB5ZmpZcWR2dGxNNTEzbGhyUklaZWtWMG9fTWU1NGtPRWRIS3AyanphRFhaYmQtTGRIX21YNkRKYS1aUDNRbFFjWnN3Ti1GX3JOc3Y?oc=5","date":"2024-10-17","type":"pipeline","source":"PR Newswire","summary":"200+ Pharma Companies Vie for the Top Spot in the Expanding Antibody-Drug Conjugate Oncology Market | DelveInsight - PR Newswire","headline":"200+ Pharma Companies Vie for the Top Spot in the Expanding Antibody-Drug Conjugate Oncology Market | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOMWdoMFd5cnJ1b0lOYmxFNWV5bG5EMHEtSmFCUURLMFpRaGVTbmNhNW1yYVp5d181bmVNTmpsSWgwSXAyV3U0dGMtY1hGNHlNZGFRU1JWU1lwc1cyaVJ5SGJRV3VLYWJLX3VpWUVKVGpaOXBFcTVLMlExUDltekN0TA?oc=5","date":"2024-05-15","type":"trial","source":"Oncology Pipeline","summary":"Bolt’s setback didn’t come out of the blue | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Bolt’s setback didn’t come out of the blue | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPX05tRzJBTEk3bFdoOXV1MmlXYzg1a1hUZEZ3OXpCdDIxczBtSEFJT2Q1SDFfWU13NTllYUo2eUxOa1JrZVJoVnhwLWJxZnJNLTlWLTRZVTd3SHl2bG5rSzhEU1BrenRBYnFXQmRSUkN4SVY0SjNydEVfSGpWdG5zT1ltOV8yTnRuaDNuTXoyZFlNN296ZmNkQVg2Rkw4X3dxMFZCTzVWOU1SZGVoT1lUbQ?oc=5","date":"2023-06-02","type":"pipeline","source":"HealthLeaders Media","summary":"Seeking Meaningful Work, Chinook Therapeutics CEO Takes on Kidney Disease - HealthLeaders Media","headline":"Seeking Meaningful Work, Chinook Therapeutics CEO Takes on Kidney Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxPclhiQzBiX2M1VmNpcjcyeVVDR1VYUEdRbmpsdkRNbExuMzBBWndJdmpRSWlQZmxzLTdyamxaUFFiR2p1Nzd2SDhqQVVqdWNtUWJsZG8wbDdkN2Jxd043UGNyVlE1cTBGRW5XRU9FUTQ3WlJKalQ2RDlma19KSHVoMzVUaWptWmR5eXJEaWxuUVFwcTlBVnNCeGdKZnljQ09jU0sxLUNRaGVRa1EwdlVLSnJINEdTS1psUk1UTktjaG15TnhGNDJOQllsZ0xOM28?oc=5","date":"2022-11-08","type":"deal","source":"GlobeNewswire","summary":"ARS Pharmaceuticals Closes Merger with Silverback Therapeutics - GlobeNewswire","headline":"ARS Pharmaceuticals Closes Merger with Silverback Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQYTJ1SGpFeldLQ0IycWhDNFh5dUZLb0hNakdoNWtWUGtFTUU5RV83ZmFOSDBsTUlXNFdvS2FpZHluMGV0R3ZfU0xUcGwtSTN3ODFrckY5cWVDdVBkbVYxeDdXeXk2ZXJ4ZEEteTF2WFhjMW9fYXg3ZjZVcVB4VUUybzFFZ01kSDVUTXRCdFY5MVh1TTFlQUN1TllHaElZRkNGMTF0akF3RjlNeTdFdDRQQzhVZ1hWdmVveENUSWNGZUhfd0JS?oc=5","date":"2022-07-26","type":"pipeline","source":"Fierce Pharma","summary":"As Silverback admits defeat, ARS troops forward to fund commercialization of epinephrine nasal spray - Fierce Pharma","headline":"As Silverback admits defeat, ARS troops forward to fund commercialization of epinephrine nasal spray","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNLXlJYnNVRkZJUXVzcHV5TnpDQnp3bnU3WjNUQUZWc2lfc2MtU3ZJTTZsUUNVN2NOYVhrVzkzakM4TjNPdlZ6TjhmeUpjTmhVYXVvdnJsWkRrQVMyUmV4VEVqazNpU3RvcXA1VEdCdVhBaDRoVERLWVU1NmxsRFExcnRxd0Z4OUlvckZNNkNMVmdJd25jRGl4dnJhZUdIcmNhT3NZSGpJUHh0TTBmMGhjTU5sTzN5cDRmNkVxR192N0xmdw?oc=5","date":"2022-07-21","type":"pipeline","source":"GeekWire","summary":"Silverback Therapeutics to merge with San Diego biotech company developing EpiPen alternative - GeekWire","headline":"Silverback Therapeutics to merge with San Diego biotech company developing EpiPen alternative","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE5KTXlXTzU5ZWg4OHVLQl9zcnRSaFlrZ09SVGNPRDVrcmY2V0F5UnhyZjBxWVhHaXhYQWNuYWRseDZDdnRzWWk3clRkUWNkZTB0WVdNSDRaU1NJZw?oc=5","date":"2020-12-05","type":"pipeline","source":"MarketBeat","summary":"Silverback Therapeutics (SBTX) Stock Price, News & Analysis - MarketBeat","headline":"Silverback Therapeutics (SBTX) Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNVFpjY0J5R3R0WDg5N1NHQU5PdWZhSTh4V09hZ1R1VzUySV9xNUFPcjdpd0RWdWRGZHlTRWVnbFljS2dkX21pVS1CV08xZ3d1QXQyZlVGeEpRbG9iSGJ6T29qa1lnWHRuQTZoZHA1NDNiVTRMakZnbnRIVHQ4NFBVWGIxZTUyU055WWtkMEtxeXB3VHBEU0lqZzBOZW05ZkgwRkU1RndjampqVFQ3bC1PY19WY0I?oc=5","date":"2020-12-03","type":"pipeline","source":"GeekWire","summary":"Silverback Therapeutics prices IPO at $21/share, will raise $241M in 4th Wash. state IPO of 2020 - GeekWire","headline":"Silverback Therapeutics prices IPO at $21/share, will raise $241M in 4th Wash. state IPO of 2020","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxNSjFKQXY5MnlBS2tucHh2b05SZThORHFSVDBMcU9xQzAtWUZQVHlzWTAxb18waGlMMXg3WWJSQ3h6ZGNoaUVocUs0VWxoRGpfS0pkTHFrUlFhNkZiRVdNUEI0cGxlcEhzeU1PS3dwelJxc3k5TVpaSFR1MzdFT082MnNib2JBUlkwX0dFemNRWktId2VKdjJXdi1QYWcxMDk0d2xfbmp3dUotNVBLYVF5Y205TXBnb0U4S0VvMWdjU0l4aThtY0x3ZU1kbWM?oc=5","date":"2020-11-30","type":"pipeline","source":"renaissancecapital.com","summary":"SBTX IPO News - Solid tumor biotech Silverback Therapeutics sets terms for $125 million IPO - renaissancecapital.com","headline":"SBTX IPO News - Solid tumor biotech Silverback Therapeutics sets terms for $125 million IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQRUs4R09PLTVrc0ZFWW1yc1pMRl9YUWdFTjdwZ1dLWDAxWk40RHo4cW93bDJCVWcwLUdTLTVUYnhQTUtiMlptNnFybWQ1anR5VDZUclF6Q19HczBTN2VhcjZueWhLNUdyZjd0R21FT2FhdjdleTlINTZZR3R3T0dfMWJJY3hISW85eUNWY0NXZ1BfWEZVUGEtT2dyRU9JZWJGSnhXcnJUMVNEcHNmQU13?oc=5","date":"2020-09-23","type":"trial","source":"Fierce Biotech","summary":"Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 - Fierce Biotech","headline":"Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":84278000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":84278000,"period":"2025-12-31"},{"value":89149000,"period":"2024-12-31"},{"value":30000,"period":"2023-12-31"},{"value":1316000,"period":"2022-12-31"},{"value":5506000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":13181000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-171298000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":41317000,"cashHistory":[],"totalAssets":327652000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}